Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH
Go back to Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH| iShares Diversified Alternatives Trust (NASDAQ: ALT) | Delayed: 3.28 +0.19 (6.15%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.09 | 52 Week High | $54.24 | |||
| Open | $3.10 | 52 Week Low | $48.35 | |||
| Day High | $3.34 | P/E | N/A | |||
| Day Low | $3.10 | EPS | $0.00 | |||
| Volume | 7,472,151 | |||||
